Compare Merck & Co., Inc. (MRK) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Weibo Corp — how do they compare? Merck & Co., Inc. trades at $141.96 (market cap $351.28B), while Weibo Corp trades at $6.55 (market cap $1.56B). The key difference: Merck & Co., Inc. is far larger — about 225.2× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (9.47%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Weibo Corp for 102 Days on average.
| MRK | WB | |
|---|---|---|
Market Cap | $351.28B | $1.56B |
Volume | 7,969,665 | 812,503 |
Sector | Health | Media |
52-Week High | $156.43 | $12.37 |
52-Week Low | $82.49 | $6.33 |
Typical Hold Time | 98 Days | 102 Days |
Enterprise Value | $398.04B | $786.69M |
Dividend Yield | 2.39% | 9.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Weibo (WB) trades at $6.55, up 1.08% on the day, with a bearish technical signal. The stock is fundamentally attractive with a low P/E of 5.32 and P/B of 0.4, while profitability remains solid with a net income margin of 17.78%. Recent Q2 2026 earnings beat expectations, though revenue growth is modest. Cash flow trends show volatility, with a significant net outflow in 2024.
The outlook is mixed; deep-value metrics and strong cash generation offer upside, but declining user metrics and advertising headwinds pose risks. Analyst consensus is divided, leaning slightly toward Hold. The stock presents a value opportunity for patient investors, contingent on stabilizing user engagement and advertising demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
